Bifogade filer
Kurs
-2,48%
Likviditet
1,38 MSEK
Prenumeration
Kalender
Est. tid* | ||
2025-11-07 | 08:30 | Kvartalsrapport 2025-Q3 |
2025-08-27 | 08:30 | Kvartalsrapport 2025-Q2 |
2025-05-20 | N/A | X-dag ordinarie utdelning SEZI 0.00 SEK |
2025-05-19 | N/A | Årsstämma |
2025-04-22 | - | Kvartalsrapport 2025-Q1 |
2025-02-17 | - | Bokslutskommuniké 2024 |
2024-11-06 | - | Kvartalsrapport 2024-Q3 |
2024-10-23 | - | Extra Bolagsstämma 2024 |
2024-08-26 | - | Kvartalsrapport 2024-Q2 |
2024-05-17 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2024-05-16 | - | Årsstämma |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-02-15 | - | Bokslutskommuniké 2023 |
2023-11-28 | - | Extra Bolagsstämma 2023 |
2023-10-26 | - | Kvartalsrapport 2023-Q3 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-17 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2023-05-16 | - | Årsstämma |
2023-04-28 | - | Kvartalsrapport 2023-Q1 |
2023-02-20 | - | Bokslutskommuniké 2022 |
2023-02-16 | - | Extra Bolagsstämma 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-07-15 | - | Kvartalsrapport 2022-Q2 |
2022-05-19 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2022-05-18 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-03-05 | - | Extra Bolagsstämma 2021 |
2021-02-26 | - | Bokslutskommuniké 2020 |
2020-11-06 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-07-02 | - | Extra Bolagsstämma 2020 |
2020-05-15 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2020-05-14 | - | Årsstämma |
2020-05-08 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-08-21 | - | Extra Bolagsstämma 2019 |
2019-05-09 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2019-05-08 | - | Årsstämma |
2019-05-08 | - | Kvartalsrapport 2019-Q1 |
2019-02-15 | - | Bokslutskommuniké 2018 |
2018-11-08 | - | Kvartalsrapport 2018-Q3 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-09 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2018-05-08 | - | Årsstämma |
2018-05-08 | - | Kvartalsrapport 2018-Q1 |
2018-03-05 | - | Extra Bolagsstämma 2018 |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-11-28 | - | Kvartalsrapport 2017-Q3 |
2017-09-15 | - | Extra Bolagsstämma 2017 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-05-23 | - | Årsstämma |
2017-05-23 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-11-22 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
2016-05-17 | - | Extra Bolagsstämma 2016 |
2016-04-28 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2016-04-27 | - | Årsstämma |
2016-04-27 | - | Kvartalsrapport 2016-Q1 |
2016-02-18 | - | Bokslutskommuniké 2015 |
2015-11-24 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-20 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2015-05-19 | - | Årsstämma |
2015-05-19 | - | Kvartalsrapport 2015-Q1 |
2015-02-25 | - | Bokslutskommuniké 2014 |
2014-11-27 | - | Kvartalsrapport 2014-Q3 |
2014-11-21 | - | Extra Bolagsstämma 2014 |
2014-08-21 | - | Kvartalsrapport 2014-Q2 |
2014-05-15 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2014-05-14 | - | Årsstämma |
2014-05-14 | - | Kvartalsrapport 2014-Q1 |
2014-02-24 | - | Bokslutskommuniké 2013 |
2013-11-27 | - | Kvartalsrapport 2013-Q3 |
2013-08-20 | - | Kvartalsrapport 2013-Q2 |
2013-05-16 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2013-05-15 | - | Årsstämma |
2013-05-15 | - | Kvartalsrapport 2013-Q1 |
2013-02-28 | - | Bokslutskommuniké 2012 |
2013-01-08 | - | Extra Bolagsstämma 2013 |
2012-11-21 | - | Kvartalsrapport 2012-Q3 |
2012-08-21 | - | Kvartalsrapport 2012-Q2 |
2012-05-24 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2012-05-23 | - | Årsstämma |
2012-05-23 | - | Kvartalsrapport 2012-Q1 |
2012-02-22 | - | Bokslutskommuniké 2011 |
2011-11-23 | - | Kvartalsrapport 2011-Q3 |
2011-08-23 | - | Kvartalsrapport 2011-Q2 |
2011-05-27 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2011-05-26 | - | Årsstämma |
2011-05-26 | - | Kvartalsrapport 2011-Q1 |
2011-02-16 | - | Bokslutskommuniké 2010 |
2010-11-24 | - | Kvartalsrapport 2010-Q3 |
2010-05-28 | - | X-dag ordinarie utdelning SEZI 0.00 SEK |
2010-05-27 | - | Kvartalsrapport 2010-Q1 |
2009-11-25 | - | Kvartalsrapport 2009-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Senzime AB (publ) (“Senzime” or the “Company”) announced on 24 August 2023 the board of directors’ resolution to carry out a directed share issue of approximately MSEK 56, at current market price. Chairman of the board, Adam Dahlberg, participated in the rights issue, which was subject to approval from the general meeting. Subscription of 1,137,500 shares has now been made and the directed share issue of approximately MSEK 56 is therefore fully subscribed.
The subscription of shares in the directed issue of shares to the Company’s chairman of the board, Adam Dahlberg, lasted until 21 September 2023 and has now concluded. The rights issue was fully subscribed, resulting in the Company raising approximately MSEK 5.1. The subscription price in the directed issue of shares was SEK 4.50 per share, which is the same subscription price as the issue of shares which was resolved and announced on 24 August 2023.
The directed issue of shares results in an increase in the number of shares in the Company by 1,137,500 shares from 98,985,114 to 100,122,614. The share capital of the Company increases by SEK 142,187.50, from SEK 12,373,139.25 to SEK 12,515,326.75. Consequently, the new issue of shares leads to a dilution of approximately 1.1% based on the total number of shares in the Company after the rights issue."
Advisers
In connection with the Share Issue, the Company has retained Zonda Partners as financial advisor and Advokatfirman Lindahl KB as legal adviser to the Company.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.
This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-09-22 13:00 CEST.